1-2 of 2
Helen McCarthy
Close
Sort by
Journal Articles

Biomarker analysis of the ASPEN study comparing zanubrutinib with ibrutinib for patients with Waldenström macroglobulinemia

Clinical Trials & Observations
Constantine S. Tam, Stephen Opat, Shirley D'Sa, Wojciech Jurczak, Hui-Peng Lee, Gavin Cull, Roger G. Owen, Paula Marlton, Björn E. Wahlin, Ramón García-Sanz, Helen McCarthy, Stephen Mulligan, Alessandra Tedeschi, Jorge J. Castillo, Jarosław Czyż, Carlos Fernández De Larrea, David Belada, Edward Libby, Jeffrey Matous, Marina Motta, Tanya Siddiqi, Monica Tani, Marek Trněný, Monique C. Minnema, Christian Buske, Véronique Leblond, Steven P. Treon, Judith Trotman, Binghao Wu, Yiling Yu, Zhirong Shen, Wai Y. Chan, Jingjing Schneider, Heather Allewelt, Aileen Cohen, Meletios A. Dimopoulos
Journal: Blood Advances
Blood Adv (2024) 8 (7): 1639–1650.
https://doi.org/10.1182/bloodadvances.2023010906
Published: 2024
Includes: Supplemental data
Journal Articles

Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia

Clinical Trials & Observations
Paul M. Barr, Carolyn Owen, Tadeusz Robak, Alessandra Tedeschi, Osnat Bairey, Jan A. Burger, Peter Hillmen, Steve E. Coutre, Claire Dearden, Sebastian Grosicki, Helen McCarthy, Jian-Yong Li, Fritz Offner, Carol Moreno, Cathy Zhou, Emily Hsu, Anita Szoke, Thomas J. Kipps, Paolo Ghia
Journal: Blood Advances
Blood Adv (2022) 6 (11): 3440–3450.
https://doi.org/10.1182/bloodadvances.2021006434
Published: 2022
Includes: Supplemental data